Meningitis Clinical Presentation

  • Author: Raymund R Razonable, MD; Chief Editor: Burke A Cunha, MD   more...
 
Updated: Jul 7, 2011
 

History

Clues in the patient's clinical history may suggest the specific etiologic agent that caused meningitis to develop. Detailed epidemiologic and predisposing risks should be assessed.

For example, in patients whose symptoms have lasted longer than 1 month and who have CSF pleocytosis, 40% of these individuals have tuberculous meningitis, 7% have cryptococcal meningitis, 8% have neoplasms, and 34% remain undiagnosed. (In these patients, defer ED treatment until the organism is identified.)

Exposures

History of exposure to a patient with a similar illness is an important epidemiologic clue when determining etiology (eg, individuals who were in close contact with an index case of meningococcemia). Record evidence of systemic viral infection (ie, myalgias, fatigue, anorexia). Enteroviral infection is suggested by the presence of exanthemas; symptoms of pericarditis, myocarditis, or conjunctivitis; or syndromes of pleurodynia, herpangina, and hand-foot-and-mouth disease.

Elicit a history of sexual contact and high-risk behavior from the patient. HSV meningitis is associated with primary genital HSV infection and HIV infection. A history of recurrent bouts of benign aseptic meningitis suggests Mollaret syndrome, which is caused by HSV.

Animal contacts should be elicited. Patients with rabies could present atypically with aseptic meningitis; rabies should be suspected in a patient with a history of animal bite (eg, skunk, raccoon, dog, fox, bat). Exposure to rodents suggests infection with LCM virus and Leptospira infection. Laboratory workers dealing with these animals also are at increased risk of contracting LCM.

The intake of unpasteurized milk and cheese predisposes to brucellosis and L monocytogenes infection.

Previous medical treatment and existing conditions

As many as 40% of patients with acute or subacute bacterial meningitis have previously been treated with oral antibiotics (presumably due to misdiagnosis at the time of initial presentation).

The presence of a ventriculoperitoneal shunt and a history of recent cranial surgery should be elicited. Patients with low-grade ventriculitis associated with a ventriculoperitoneal shunt may have a less dramatic presentation than do patients with acute bacterial meningitis, with headache, nausea, minimal fever, and malaise.

The presence of cochlear implants with a positioner has been associated with a higher risk of bacterial meningitis.

Multiple etiologies of fever and seizures in patients with alcoholism or cirrhosis make meningitis challenging to diagnose.

Location and travel

Geographic location and travel history are important in the evaluation of patients. H capsulatum and B dermatitidis are considered in patients with exposure to endemic areas of the Mississippi and Ohio River valleys; C immitis is considered in regions of the southwestern United States, Mexico, and Central America; and B burgdorferi is considered in regions of the northeastern and northern central United States.

Season and temperature

The time of year is an important variable because many infections are seasonal. Enteroviruses are observed worldwide, and infections occur during late summer and early fall in temperate climates and year-round in tropical regions. In contrast, mumps, measles, and varicella-zoster viruses occur more commonly during winter and spring. Arthropod-borne viruses (eg, St. Louis encephalitis, California encephalitis virus group) occur during the warmer months.

Next

Physical Examination

Distinguishing acute, subacute, and chronic meningitis helps to identify the causative pathogen for these diseases.

Bacterial and viral meningitis

Otherwise healthy patients within age extremes present with clinically obvious acute bacterial meningitis. In contrast, most patients with subacute bacterial meningitis present a diagnostic challenge. Systemic examination occasionally reveals a pulmonary or otitis media co-infection.

Signs of meningeal irritation include the following:

  • Nuchal rigidity or discomfort on neck flexion
  • Kernig sign
  • Brudzinski sign

Papilledema is present in only one third of meningitis patients with increased ICP; it takes at least several hours to develop.

Focal neurologic signs include the following:

  • Isolated cranial nerve abnormalities (principally III, IV, VI, VII) in 10-20% of patients
  • Dramatic increase in complications from lumbar puncture, portending a worse outcome

Systemic findings can also be present. Extracranial infection (eg, sinusitis, otitis media, mastoiditis, pneumonia, urinary tract infection) may be noted. Arthritis is seen with N meningitidis but is found less commonly with other bacterial species.

Nonblanching petechiae and cutaneous hemorrhages are seen classically with N meningitidis; however, these also can occur with other bacterial and viral infections. Endotoxic shock with vascular collapse is characteristic of severe N meningitidis infection. Altered mental status, from irritability to somnolence, delirium, and coma, can develop.

Infants may have the following:

  • Bulging fontanelle (if euvolemic)
  • Paradoxic irritability (ie, quiet when stationary, cries when held)
  • High-pitched cry
  • Hypotonia
  • Examine skin over entire spine for dimples, sinuses, nevi, or tufts of hair, which may indicate a congenital anomaly communicating with the subarachnoid space.

Approximately 25% of patients with bacterial meningitis present acutely, well within 24 hours of onset of symptoms. In contrast, patients with subacute bacterial meningitis and most patients with viral meningitis present with neurologic symptoms developing over 1-7 days. Chronic symptoms lasting longer than 1 week suggest the presence of meningitis caused by certain viruses or by tuberculosis, syphilis, fungi (especially cryptococci), or carcinomatosis.

About 85% of adults and children with bacterial meningitis exhibit the classic triad of symptoms (ie, fever, headache, and neck stiffness).[5] These symptoms can develop over several hours or over 1-2 days. Fever is the most common manifestation (95%), while the other 2 symptoms are less common.

However, in a meta-analysis of 845 patients, the sensitivity and specificity of these classic symptoms were poor. Even so, the negative predictive value of these symptoms is high (ie, the absence of fever, neck stiffness, or altered mental status eliminates the diagnosis of meningitis in 99-100% of cases).

Other symptoms can include the following:

  • Nausea
  • Vomiting
  • Photalgia - Discomfort when the patient looks into bright lights (also called photophobia)
  • Sleepiness
  • Confusion
  • Irritability
  • Delirium
  • Coma

Increased blood pressure with bradycardia can also be present. Vomiting occurs in 35% of patients. Occasionally, if a patient has been taking antibiotics for another infection, meningitis symptoms can take longer to develop or may be less intense.

On physical examination, a skin rash caused by meningococcal meningitis (50%), H influenzae, pneumococcal meningitis, echovirus type 9, or Staphylococcus aureus may be present.[9] Other neurologic signs include the following:

  • Cranial nerve palsies - Resulting from ICP or the presence of exudates encasing the nerve roots
  • Focal cerebral signs (10-20%) - May develop as a result of ischemia from vascular inflammation and thrombosis
  • Papilledema (< 1%) - Another sign of increased ICP; presence of papilledema suggests not only meningitis but a possible alternate diagnosis (eg, brain abscess)

One quarter of affected patients have a fulminant onset within 24 hours of infection, and there may be a history of a respiratory illness within the preceding 7 days (50%).

Patients with meningitis caused by the mumps virus usually present with the triad of fever, vomiting, and headache. It follows the onset of parotitis (salivary gland enlargement occurs in 50% of patients), which clinically resolves in 7-10 days.

As bacterial meningitis progresses, patients of any age may have seizures (30% of adults and children; 40% of newborns and infants). As many as 40% of patients with acute or subacute bacterial meningitis have previously been treated with oral antibiotics (presumably due to misdiagnosis at time of initial presentation); in patients with partially treated meningitis, seizures may be the sole presenting symptom. Fever and changes in level of alertness or mental status occur less commonly than in untreated meningitis.

Atypical presentation may be observed in certain groups. Elderly individuals, especially those with underlying comorbidities (eg, diabetes, renal and liver disease), may present with lethargy and an absence of meningeal symptoms. Patients with neutropenia may present with subtle symptoms of meningeal irritation. Other immunocompromised hosts, including organ and tissue transplant recipients and patients with HIV and AIDS, may also have an atypical presentation. Immunosuppressed patients may not show dramatic signs of fever or meningeal inflammation.

A less dramatic presentation―headache, nausea, minimal fever, and malaise―may be found in patients with low-grade ventriculitis associated with a ventriculoperitoneal shunt. Newborns and small infants also may not present with the classic symptoms, or the symptoms may be difficult to detect. An infant may appear only to be slow or inactive, or he or she may be irritable, vomiting, or feeding poorly. Other symptoms in this age group include temperature instability, high-pitched crying, respiratory distress, and/or bulging fontanelles (late sign in one third of neonates).

Approximately half of affected adults show signs of meningeal irritation, such as nuchal and/or spinal rigidity and a positive Kernig and/or Brudzinski sign.[9] The Kernig sign is determined in a supine patient by flexing the hip to 90° while the knee is flexed at 90°; an attempt to further extend the knee produces pain in the hamstrings and resistance to further extension. The Brudzinski sign is determined by passively flexing the neck while the patient is in a supine position with extremities extended; this maneuver produces flexion of the hips in patients with meningeal irritation.

Resistance to passive flexion of the neck is also a sign. Exacerbation of existing headache by repeated horizontal movement of the head, at a rate of 2-3 times per second, may also suggest meningeal irritation.

Systemic findings on physical examination may provide clues to the etiology of a patient’s meningitis. Morbilliform rash with pharyngitis and adenopathy may suggest a viral etiology (eg, EBV, CMV, adenovirus, HIV). Macules and petechiae that rapidly evolve into purpura suggest meningococcemia (with or without meningitis). Vesicular lesions in a dermatomal distribution suggest varicella-zoster virus. Genital vesicles suggest HSV-2 meningitis.

Sinusitis or otitis suggests direct extension into the meninges, usually with S pneumoniae and H influenzae. Rhinorrhea or otorrhea suggests a CSF leak from a basilar skull fracture, with meningitis most commonly caused by S pneumoniae.

Hepatosplenomegaly and lymphadenopathy suggest a systemic disease, including viral (eg, mononucleosis-like syndrome in EBV, CMV, and HIV) and fungal (eg, disseminated histoplasmosis).

The presence of a murmur suggests infective endocarditis with secondary bacterial seeding of the meninges.

General physical findings in viral meningitis are common to all causative agents, but some viruses produce unique clinical manifestations that help in focusing the diagnostic approach. The classically taught triad of meningitis consists of fever, nuchal rigidity, and altered mental status, but not all patients have all 3 symptoms, and almost all patients have headache. The examination reveals no focal neurologic deficits in the majority of cases.

Chronic meningitis

Perform careful general, systemic, and neurologic examinations, looking especially for a BCG vaccination scar, lymphadenopathy, papilledema and tuberculomas during funduscopy, and meningismus.

The presentation of chronic tuberculous meningitis may be acute, but the classic presentation is subacute and spans weeks. Patients generally have a prodrome of fever of varying degrees, malaise, and intermittent headaches. Patients often develop central nerve palsies (III, IV, V, VI, and VII), suggesting basilar meningeal involvement.

Clinical staging of tuberculous meningitis is based on neurologic status, as follows:

  • Stage 1 - No change in mental function with no deficits and no hydrocephalus
  • Stage 2 - Confusion and evidence of neurologic deficit
  • Stage 3 - Stupor and lethargy

The median incubation period before the appearance of symptoms in chronic syphilitic meningitis is 21 days (range 3-90 d), during which time spirochetemia develops. Three stages of disease are described, and involvement of the CNS can occur during any of these stages.

Syphilitic meningitis usually occurs during the primary or secondary stage, complicating 0.3-2.4% of primary infections during the first 2 years. Its presentation is similar to other types of aseptic meningitis, with headache, nausea, vomiting, and meningismus.

Meningovascular syphilis occurs later in the course of untreated syphilis, and the symptoms are dominated by focal syphilitic arteritis (ie, focal neurologic symptoms associated with signs of meningeal irritation) that spans weeks to months and results in stroke and irreversible damage if left untreated. Patients with HIV have an increased risk of accelerated progression.

Although rare during stage I of Lyme disease, CNS involvement (with meningitis) may occur in Lyme disease-associated chronic meningitis and is characterized by the concurrent appearance of erythema migrans at the site of the tick bite. More commonly, aseptic meningitis syndrome occurs 2-10 weeks following the erythema migrans rash. This represents stage 2 of Lyme disease, or the borrelial hematogenous dissemination stage.

Headache is the most common symptom of Lyme disease–associated chronic meningitis, with photophobia, nausea, and neck stiffness occurring less frequently. Symptoms of somnolence, emotional lability, and impaired memory and concentration may occur. Facial nerve palsy is the most common cranial nerve deficit. These symptoms of meningitis usually fluctuate and may last for months if left untreated.

Infection with C neoformans is characterized by the gradual onset of symptoms, the most common of which is headache.

Coccidioidal meningitis is the most serious form of dissemination, and it usually is fatal if left untreated. These patients may present with headache, vomiting, and altered mental function associated with pleocytosis, elevated protein levels, and decreased glucose levels. Eosinophils may be a prominent finding in the CSF.

Patients infected with B dermatitidis may present with an abscess or fulminant meningitis, while patients infected with H capsulatum may present with headache, cranial nerve deficits, or changes in mental status months prior to diagnosis.

Helminthic eosinophilic meningitis

Following ingestion of A cantonensis, most patients with symptomatic disease present with nonspecific and self-limited abdominal pain caused by larval migration into the bowel wall. On rare occasions, the larvae can migrate into the CNS and cause eosinophilic meningitis.

Aseptic meningitis

In contrast to patients with bacterial meningitis, patients with aseptic meningitis syndrome usually appear clinically nontoxic, with no vascular instability. In many cases, a cause for meningitis is not apparent after initial evaluation and is therefore classified as aseptic meningitis. These patients characteristically have an acute onset of meningeal symptoms, fever, and cerebrospinal pleocytosis that is usually prominently lymphocytic.

Go to Aseptic Meningitis for complete information on this topic.

Previous
Next

Complications

Risk factors for hearing loss after pneumococcal meningitis are female gender, older age, severe meningitis, and infection with certain pneumococcal serotypes (eg, 12F serotype).[10] In 50% of patients, several complications may develop in the days to weeks following infection.

Immediate complications include the following:

  • Septic shock, including DIC
  • Coma with loss of protective airway reflexes
  • Seizures - 30-40% of children, 20-30% of adults
  • Cerebral edema
  • Septic arthritis
  • Pericardial effusion
  • Hemolytic anemia (H influenzae)

Delayed complications include the following:

  • Decreased hearing or deafness
  • Other cranial nerve dysfunctions
  • Multiple seizures
  • Focal paralysis
  • Subdural effusions
  • Hydrocephalus
  • Intellectual deficits
  • Ataxia
  • Blindness
  • Waterhouse-Friderichsen syndrome
  • Peripheral gangrene

Seizures

Seizures are a common and important complication that occur in approximately one fifth of patients. The incidence is higher in patients younger than 1 year, reaching 40%. Approximately one half of patients with this complication have repeated seizures. Patients die as a result of diffuse CNS ischemic injury or from systemic complications.

Even with effective antimicrobial therapy, significant neurologic complications have been reported to occur in as many as 30% of survivors following an episode of bacterial meningitis. Closely monitor for the development of these complications.

Cerebral edema

Some degree of cerebral edema is common with bacterial meningitis. This complication is an important cause of death.

Cranial nerve palsy and cerebral infarction

Cranial nerve palsies and the effects of impaired cerebral blood flow, such as cerebral infarction, are caused by increased ICP. In certain cases, repeated lumbar puncture or the insertion of a ventricular drain may be necessary to relieve the effects of this increase.

In cerebral infarction, endothelial cells swell, proliferate, and crowd into the lumen of the blood vessel, and inflammatory cells infiltrate the blood vessel wall. Foci of necrosis develop in the arterial and venous walls and induce arterial and venous thrombosis. Venous thrombosis is more frequent than arterial thrombosis, but arterial and venous cerebral infarctions can be seen in 30% of patients.

Brain parenchymal damage

Brain parenchymal damage is the most important and feared complication of bacterial meningitis. It can lead to the following disorders:

  • Sensory and motor deficits
  • Cerebral palsy
  • Learning disabilities
  • Mental retardation
  • Cortical blindness
  • Seizures

Cerebritis

Inflammation often extends along the perivascular (Virchow-Robin) spaces into the underlying brain parenchyma. Commonly, cerebritis results from direct spread of infection, either from otorhinologic infection or meningitis (including retrograde septic thrombophlebitis) or from hematogenous spread from an extracranial focus of infection. Parenchymal involvement, with edema and mass effect, may be localized or diffuse. Cerebritis can evolve to frank abscess formation in the gray matter–white matter junction.

Subdural effusion

In children with meningitis who are younger than 1 year, 20-50% of cases are complicated by sterile subdural effusions. Most cases are transient and small to moderate in size. Of these effusions, 2% are infected secondarily and become subdural empyemas. In the empyema, infection and necrosis of the arachnoid membrane permits formation of a subdural collection.

Risk factors include young age, rapid onset of illness, low peripheral WBC count, and high CSF protein. Seizures occur more commonly during the acute course of the disease, although long-term sequelae of promptly treated subdural effusions are similar to those of uncomplicated meningitis.

Ventriculitis

Ventriculitis may occur through the involvement of the ependymal lining of the ventricles in 30% of patients. This complication is especially common in neonates, with an incidence as high as 92%. The organisms enter the ventricles via the choroid plexuses. As a result of reduced CSF flow, and possibly reduced secretion of CSF by the choroid plexus, the infective organisms remain in the ventricles and multiply.

Ventriculomegaly

Ventriculomegaly can occur early or late in the course of meningitis and is usually transient and mild to moderate in severity. As a result of the subarachnoid inflammatory exudate, CSF pathways may become obstructed, leading to hydrocephalus. Exudates in the foramina of Luschka and Magendie can cause noncommunicating hydrocephalus, whereas exudates that accumulate in the basilar cisterns or over the cerebral convexity can develop into communicating hydrocephalus.

Previous
 
 
Contributor Information and Disclosures
Author

Raymund R Razonable, MD  Consultant, Division of Infectious Diseases, Mayo Clinic of Rochester; Associate Professor of Medicine, Mayo Clinic College of Medicine

Raymund R Razonable, MD is a member of the following medical societies: American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, and International Immunocompromised Host Society

Disclosure: Nothing to disclose.

Coauthor(s)

Robert Cavaliere, MD  Assistant Professor of Neurology, Neurosurgery and Medicine, Ohio State University College of Medicine

Disclosure: Nothing to disclose.

Francisco de Assis Aquino Gondim, MD, MSc, PhD  Associate Professor of Neurology, Department of Neurology and Psychiatry, St Louis University School of Medicine

Francisco de Assis Aquino Gondim, MD, MSc, PhD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Movement Disorders Society

Disclosure: Nothing to disclose.

Alan Greenberg, MD  Director, Associate Professor, Department of Internal Medicine, Jersey City Medical Center, Seton Hall University

Alan Greenberg, MD is a member of the following medical societies: Alpha Omega Alpha and American College of Physicians

Disclosure: Nothing to disclose.

Ronald A Greenfield, MD  Professor, Department of Internal Medicine, University of Oklahoma College of Medicine

Ronald A Greenfield, MD is a member of the following medical societies: American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Central Society for Clinical Research, Infectious Diseases Society of America, Medical Mycology Society of the Americas, Phi Beta Kappa, Southern Society for Clinical Investigation, and Southwestern Association of Clinical Microbiology

Disclosure: Pfizer Honoraria Speaking and teaching; Gilead Honoraria Speaking and teaching; Ortho McNeil Honoraria Speaking and teaching; Abbott Honoraria Speaking and teaching; Astellas Honoraria Speaking and teaching; Cubist Honoraria Speaking and teaching; Forest Pharmaceuticals Speaking and teaching

J Stephen Huff, MD  Associate Professor of Emergency Medicine and Neurology, Department of Emergency Medicine, University of Virginia School of Medicine

J Stephen Huff, MD is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Neurology, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Lutfi Incesu, MD  Professor, Department of Radiology, Ondokuz Mayis University School of Medicine; Chief, Neuroradiology and MR Unit, Department of Radiology, Ondokuz Mayis University Hospital, Turkey

Lutfi Incesu, MD is a member of the following medical societies: American Society of Neuroradiology and Radiological Society of North America

Disclosure: Nothing to disclose.

Michael R Keating, MD  Associate Professor of Medicine, Chair, Division of Infectious Diseases, Department of Medicine, Mayo Clinic College of Medicine

Michael R Keating, MD is a member of the following medical societies: American College of Physicians, American Medical Association, American Society for Microbiology, American Society of Transplantation, Infectious Diseases Society of America, and International Immunocompromised Host Society

Disclosure: Nothing to disclose.

Anil Khosla, MBBS, MD  Assistant Professor, Department of Radiology, St Louis University School of Medicine, Veterans Affairs Medical Center of St Louis

Anil Khosla, MBBS, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, American Society of Neuroradiology, North American Spine Society, and Radiological Society of North America

Disclosure: Nothing to disclose.

Rick Kulkarni, MD  Attending Physician, Department of Emergency Medicine, Cambridge Health Alliance, Division of Emergency Medicine, Harvard Medical School

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

Marjorie Lazoff, MD  Editor-in-Chief, Medical Computing Review

Marjorie Lazoff, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Emergency Physicians, American Medical Informatics Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Glenn Lopate, MD  Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Director of Neurology Clinic, St Louis ConnectCare; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa

Disclosure: Baxter Grant/research funds Other; Amgen Grant/research funds None

C Douglas Phillips, MD  Director of Head and Neck Imaging, Division of Neuroradiology, New York Presbyterian Hospital, Weill Cornell Medical College

C Douglas Phillips, MD is a member of the following medical societies: American College of Radiology, American Medical Association, American Society of Head and Neck Radiology, American Society of Neuroradiology, Association of University Radiologists, and Radiological Society of North America

Disclosure: Nothing to disclose.

Tarakad S Ramachandran, MBBS, FRCP(C), FACP  Professor of Neurology, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Chair, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, FRCP(C), FACP is a member of the following medical societies: American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners, American College of International Physicians, American College of Managed Care Medicine, American College of Physicians, American Heart Association, American Stroke Association, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, and Royal Society of Medicine

Disclosure: Abbott Labs None None; Teva Marion None None; Boeringer-Ingelheim Honoraria Speaking and teaching

Norman C Reynolds Jr, MD  Neurologist, Veterans Affairs Medical Center of Milwaukee; Clinical Professor, Medical College of Wisconsin

Norman C Reynolds Jr, MD is a member of the following medical societies: American Academy of Neurology, Association of Military Surgeons of the US, Movement Disorders Society, Sigma Xi, and Society for Neuroscience

Disclosure: Nothing to disclose.

Robert Stanley Rust Jr, MD, MA  Thomas E Worrell Jr Professor of Epileptology and Neurology, Co-Director of FE Dreifuss Child Neurology and Epilepsy Clinics, Director, Child Neurology, University of Virginia School of Medicine; Chair-Elect, Child Neurology Section, American Academy of Neurology

Robert Stanley Rust Jr, MD, MA is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, American Headache Society, American Neurological Association, Child Neurology Society, International Child Neurology Association, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Manish K Singh, MD  Assistant Professor, Department of Neurology, Teaching Faculty for Pain Management and Neurology Residency Program, Hahnemann University Hospital, Drexel College of Medicine; Medical Director, Neurology and Pain Management, Jersey Institute of Neuroscience

Manish K Singh, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pain Medicine, American Association of Physicians of Indian Origin, American Headache Society, American Medical Association, and American Society of Regional Anesthesia and Pain Medicine

Disclosure: Nothing to disclose.

Niranjan N Singh, MD, DNB  Assistant Professor of Neurology, University of Missouri-Columbia School of Medicine

Niranjan N Singh, MD, DNB is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Mark S Slabinski, MD, FACEP, FAAEM  Vice President, EMP Medical Group

Mark S Slabinski, MD, FACEP, FAAEM is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Ohio State Medical Association

Disclosure: Nothing to disclose.

James G Smirniotopoulos, MD  Professor of Radiology, Neurology, and Biomedical Informatics, Program Director, Diagnostic Imaging Program, Center for Neuroscience and Regenerative Medicine (CNRM), Uniformed Services University of the Health Sciences

James G Smirniotopoulos, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, American Society of Head and Neck Radiology, American Society of Neuroradiology, American Society of Pediatric Neuroradiology, Association of University Radiologists, and Radiological Society of North America

Disclosure: Nothing to disclose.

Florian P Thomas, MD, MA, PhD, Drmed  Director, Spinal Cord Injury Unit, St Louis Veterans Affairs Medical Center; Director, National MS Society Multiple Sclerosis Center; Director, Neuropathy Association Center of Excellence, Professor, Department of Neurology and Psychiatry, Associate Professor, Institute for Molecular Virology, and Department of Molecular Microbiology and Immunology, St Louis University School of Medicine

Florian P Thomas, MD, MA, PhD, Drmed is a member of the following medical societies: American Academy of Neurology, American Neurological Association, American Paraplegia Society, Consortium of Multiple Sclerosis Centers, and National Multiple Sclerosis Society

Disclosure: Nothing to disclose.

Frederick M Vincent Sr, MD  Clinical Professor, Department of Neurology and Ophthalmology, Michigan State University Colleges of Human and Osteopathic Medicine

Frederick M Vincent Sr, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American College of Forensic Examiners, American College of Legal Medicine, American College of Physicians, and Michigan State Medical Society

Disclosure: Nothing to disclose.

Amir Vokshoor, MD  Staff Neurosurgeon, Department of Neurosurgery, Spine Surgeon, Diagnostic and Interventional Spinal Care, St John's Health Center

Amir Vokshoor, MD is a member of the following medical societies: Alpha Omega Alpha, American Association of Neurological Surgeons, American Medical Association, and North American Spine Society

Disclosure: Nothing to disclose.

Cordia Wan, MD  Adult Neurologist, Kaiser Permanente Hawaii, Kaiser Permanente Southern California

Cordia Wan, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Eric L Weiss, MD, DTM&H  Medical Director, Office of Service Continuity and Disaster Planning, Fellowship Director, Stanford University Medical Center Disaster Medicine Fellowship, Chairman, SUMC and LPCH Bioterrorism and Emergency Preparedness Task Force, Clinical Associate Progressor, Department of Surgery (Emergency Medicine), Stanford University Medical Center

Eric L Weiss, MD, DTM&H is a member of the following medical societies: American College of Emergency Physicians, American College of Occupational and Environmental Medicine, American Medical Association, American Society of Tropical Medicine and Hygiene, Physicians for Social Responsibility, Southeastern Surgical Congress, Southern Association for Oncology, Southern Clinical Neurological Society, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Lawrence A Zumo, MD  Neurologist, Private Practice

Lawrence A Zumo, MD is a member of the following medical societies: American Academy of Neurology, American College of Physicians, American Medical Association, and Southern Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Joseph Richard Masci, MD  Professor of Medicine, Professor of Preventive Medicine, Mount Sinai School of Medicine; Director of Medicine, Elmhurst Hospital Center

Joseph Richard Masci, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, Association of Professors of Medicine, and Royal Society of Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

John W King, MD  Professor of Medicine, Chief, Section of Infectious Diseases, Director, Viral Therapeutics Clinics for Hepatitis, Louisiana State University Health Sciences Center; Consultant in Infectious Diseases, Overton Brooks Veterans Affairs Medical Center

John W King, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Association of Subspecialty Professors, Infectious Diseases Society of America, and Sigma Xi

Disclosure: emedicine $50.00 Author of chapter; MERCK None Other

Karen L Roos, MD  John and Nancy Nelson Professor of Neurology, Professor of Neurological Surgery, Department of Neurology, Indiana University School of Medicine

Karen L Roos, MD is a member of the following medical societies: American Academy of Neurology and American Neurological Association

Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors Sidney E Croul, MD, Timothy Brannan, MD, Pieter R Kark, MD, Suur Biliciler, MD, Prem C Shukla, MD, and Uma Iyer, MD, to the development and writing of the source articles.

References
  1. Mann K, Jackson MA. Meningitis. Pediatr Rev. Dec 2008;29(12):417-29; quiz 430. [Medline].

  2. Ginsberg L, Kidd D. Chronic and recurrent meningitis. Pract Neurol. Dec 2008;8(6):348-61. [Medline].

  3. Berkhout B. Infectious diseases of the nervous system: pathogenesis and worldwide impact. IDrugs. Nov 2008;11(11):791-5. [Medline].

  4. Nkoumou MO, Clevenbergh P, Betha G, Kombila M. Bacterial meningitis in HIV positive compared to HIV negative patients in an internal medicine ward of Librevile, Gabon. . Int Conf AIDS: International Conference on AIDS. Jul 7-12 2002;abstract no. ThPeB7368.

  5. Scheld WM, Koedel U, Nathan B, Pfister HW. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J Infect Dis. Dec 1 2002;186 Suppl 2:S225-33. [Medline].

  6. Thigpen, M, Rosenstein, NE, Whitney, CG. Bacterial meningitis in the United States --1998-2003. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA. October 2005;65.

  7. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. May 26 2011;364(21):2016-25. [Medline].

  8. van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med. Jan 5 2006;354(1):44-53. [Medline].

  9. Moses S. Meningitis: acute bacterial meningitis. Accessed February 8, 2011. Available at http://www.fpnotebook.com/neuro/ID/Mngts.htm.

  10. Worsoe L, Caye-Thomasen P, Brandt CT, Thomsen J, Ostergaard C. Factors associated with the occurrence of hearing loss after pneumococcal meningitis. Clin Infect Dis. Oct 15 2010;51(8):917-24. [Medline].

  11. [Best Evidence] Dubos F, Korczowski B, Aygun DA, Martinot A, Prat C, Galetto-Lacour A, et al. Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. Arch Pediatr Adolesc Med. Dec 2008;162(12):1157-63. [Medline].

  12. Gilbert DN, Moellering RC Jr, Sande MA. Antimicrobial Therapy. In: Sanford Guide to Antimicrobial Therapy. 33rd ed. March 15, 2003.

  13. van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis. Mar 2004;4(3):139-43. [Medline].

  14. van de Beek D, de Gans J. Dexamethasone and pneumococcal meningitis. Ann Intern Med. Aug 17 2004;141(4):327. [Medline].

  15. Peltola H, Roine I. Improving the outcomes in children with bacterial meningitis. Curr Opin Infect Dis. Jun 2009;22(3):250-5. [Medline].

  16. [Best Evidence] Sloan D, Dlamini S, Paul N, Dedicoat M. Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. Cochrane Database Syst Rev. Oct 8 2008;CD005647. [Medline].

  17. Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep. May 2 2008;57(17):462-5. [Medline].

  18. [Guideline] Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. Jan 28 2011;60(3):72-6. [Medline]. [Full Text].

  19. Seupaul RA. Evidence-based emergency medicine/rational clinical examination abstract. How do I perform a lumbar puncture and analyze the results to diagnose bacterial meningitis?. Ann Emerg Med. Jul 2007;50(1):85-7. [Medline].

Previous
Next
 
Pneumococcal meningitis in a patient with alcoholism. Courtesy of the CDC/Dr. Edwin P. Ewing, Jr.
Acute bacterial meningitis. This axial nonenhanced computed tomography scan shows mild ventriculomegaly and sulcal effacement
Acute bacterial meningitis. This axial T2-weighted magnetic resonance image shows only mild ventriculomegaly.
Acute bacterial meningitis. This contrast-enhanced, axial T1-weighted magnetic resonance image shows leptomeningeal enhancement (arrows).
Chronic mastoiditis and epidural empyema in a patient with bacterial meningitis. This axial computed tomography scan shows sclerosis of the temporal bone (chronic mastoiditis), an adjacent epidural empyema with marked dural enhancement (arrow), and the absence of left mastoid air.
Subdural empyema and arterial infarct in a patient with bacterial meningitis. This contrast-enhanced axial computed tomography scan shows left-sided parenchymal hypoattenuation in the middle cerebral artery territory, with marked herniation and a prominent subdural empyema.
Table 1. Infectious Agents Causing Aseptic Meningitis Syndrome
Category Agent
BacteriaPartially-treated bacterial meningitis



L monocytogenes



Brucella species



Rickettsia rickettsii



Ehrlichia species



Mycoplasma pneumoniae



Borrelia burgdorferi



Treponema pallidum



Leptospira species



Mycobacterium tuberculosis



Nocardia species



ParasitesN fowleri



Acanthamoeba species



Balamuthia species



Angiostrongylus cantonensis



G spinigerum



Baylisascaris procyonis



S stercoralis



Taenia solium (cysticercosis)



FungiCryptococcus neoformans



C immitis



Blastomyces dermatitidis



H capsulatum



Candida species



Aspergillus species



VirusesEnterovirus



Poliovirus



Echovirus



Coxsackievirus A



Coxsackievirus B



Enterovirus 68-71



Herpesvirus



HSV-1 and HSV-2



Varicella-zoster virus



EBV



CMV



HHV*-6



HHV-7



Paramyxovirus



Mumps virus



Measles virus



Togavirus



Rubella virus



Flavivirus



Japanese encephalitis virus



St. Louis encephalitis virus



Bunyavirus



California encephalitis virus



La Crosse encephalitis virus



Alphavirus



Eastern equine encephalitis virus



Western equine encephalitis virus



Venezuelan encephalitis virus



Reovirus



Colorado tick fever virus



Arenavirus



LCM virus**



Rhabdovirus



Rabies virus



Retrovirus



HIV***



*Human herpes virus



**Lymphocytic choriomeningitis



***Human immunodeficiency virus



Table 2. Causes of Chronic Meningitis
Category Agent
BacteriaM tuberculosis



B burgdorferi



T pallidum



Brucella species



Francisella tularensis



Nocardia species



Actinomyces species



FungiC neoformans



C immitis



B dermatitidis



H capsulatum



Candida albicans



Aspergillus species



Sporothrix schenckii



ParasitesAcanthamoeba species



N fowleri



Angiostrongylus cantonensis



G spinigerum



B procyonis



Schistosoma species



S stercoralis



Echinococcus granulosus



Table 3. Changing Epidemiology of Acute Bacterial Meningitis in the United States*
Bacteria 1978-1981 1986 1995 1998-2007
H influenzae48%45%7%6.7%
Listeria monocytogenes2%3%8%3.4%
N meningitidis20%14%25%13.9%
S agalactiae3%6%12%18.1%
S pneumoniae13%18%47%58%
*Nosocomial meningitis is not included. These data include only the 5 major meningeal pathogens.
Table 4. The Most Common Bacterial Pathogens Based on Age and Predisposing Risks
Risk and/or Predisposing Factor Bacterial Pathogen
Age 0-4 weeksStreptococcus agalactiae (group B streptococci)



E coli K1



Listeria monocytogenes



Age 4-12 weeksS agalactiae



E coli



H influenzae



S pneumoniae



N meningitidis



Age 3 months to 18 yearsN meningitidis



S pneumoniae



H influenzae



Age 18-50 yearsS pneumoniae



N meningitidis



H influenzae



Age older than 50 yearsS pneumoniae



N meningitidis



L monocytogenes



Aerobic gram-negative bacilli



Immunocompromised stateS pneumoniae



N meningitidis



L monocytogenes



Aerobic gram-negative bacilli



Intracranial manipulation, including neurosurgeryStaphylococcus aureus



Coagulase-negative staphylococci



Aerobic gram-negative bacilli, including



P aeruginosa



Basilar skull fractureS pneumoniae



H influenzae



Group A streptococci



CSF shuntsCoagulase-negative staphylococci



S aureus



Aerobic gram-negative bacilli



Propionibacterium acnes



Table 5. CSF Picture of Meningitis According to Etiologic Agent
Agent Opening Pressure WBC count per µL Glucose (mg/dL) Protein (mg/dL) Microbiology
Bacterial meningitis200-300100-5000; >80% PMNs*< 40>100Specific pathogen demonstrated in 60% of Gram stains and 80% of cultures
Viral meningitis90-20010-300; lymphocytesNormal, reduced in LCM and mumpsNormal but may be slightly elevatedViral isolation, PCR assays
Tuberculous meningitis180-300100-500; lymphocytesReduced, < 40Elevated, >100Acid-fast bacillus stain, culture, PCR
Cryptococcal meningitis180-30010-200; lymphocytesReduced50-200India ink, cryptococcal antigen, culture
Aseptic meningitis90-20010-300; lymphocytesNormalNormal but may be slightly elevatedNegative findings on workup
Normal values80-2000-5; lymphocytes50-7515-40Negative findings on workup
*Polymorphonuclear lymphocytes



†Polymerase chain reaction



Table 6. Comparison of CSF Findings by Type of Organism
Bacterial Meningitis Viral Meningitis* Fungal Meningitis**
Pressure



5-15 cm H2 O



IncreasedNormal or mildly increasedNormal or mildly increased in TB. May be increased in fungal. AIDS patients with cryptococcal meningitis have increased risk of blindness, death unless maintained at < 30 cm.
Cell count



preterm: 0-25



term: 0-22



>6 months: 0-5



mononuclear



cells/mm3



No cell count result can exclude bacterial meningitis. Typically thousands of PMNs, but may be less dramatic or even normal (classically, in very early meningococcal meningitis and in extremely ill neonates). Lymphocytosis with normal CSF chemistries seen in 15-25%, especially when cell counts < 1000 or if partially treated. Approximately 90% of patients with ventriculoperitoneal shunts have CSF WBC count >100 cells/mm3 are infected; CSF glucose usually normal, and organisms are less pathogenic. Cell count and chemistries normalize slowly (over days) with antibiotics. Usually < 500 cells, nearly 100% mononuclear. Up to 48 hours, significant PMN pleocytosis may be indistinguishable from early bacterial meningitis; this is particularly true with eastern equine encephalitis. Presence of nontraumatic



RBCs in 80% of HSV meningoencephalitis, although 10% have normal CSF results



Hundreds of mononuclear cells
Micro



no organisms



Gram stain 80% sensitive. Inadequate decolorization may mistake H influenzae for gram-positive cocci. Pretreatment with antibiotics may affect stain uptake, causing gram-positive organisms to appear gram negative and decrease culture yield on average 20%. No organismIndia ink 80-90% sensitive for fungi; AFB stain 40% sensitive for TB (increase yield by staining supernate from at least 5 cc CSF)
Glucose



euglycemia: >50% serum



hyperglycemia: >30% serum



wait 4 h after glucose load



DecreasedNormalSometimes decreased. Aside from fulminant bacterial meningitis, the lowest levels of CSF glucose are seen in TB, primary amebic meningoencephalitis, neurocysticercosis
Protein



preterm: 65-150



term: 20-170



>6 months: 15-45



mg/dL



Usually >150, may be >1000Mildly increasedIncreased; >1000 with relatively benign clinical presentation suggestive of fungal disease
*Some bacteria (eg, Mycoplasma, Listeria, Leptospira species, Borrelia burgdorferi [Lyme], spirochetes) produce spinal fluid alterations that resemble the viral profile. An aseptic profile also is typical of partially treated bacterial infections (more than 33% of patients have received antimicrobial treatment, especially children) and the 2 most common causes of encephalitis — the potentially curable HSV and arboviruses.



**In contrast, tuberculous meningitis and parasites resemble the fungal profile more closely.



Table 7. Recommended Empiric Antibiotics According to Predisposing Factors for Patients With Suspected Bacterial Meningitis
Predisposing Feature Antibiotic(s)
Age 0-4 weeksAmpicillin plus cefotaxime or an aminoglycoside
Age 1-3 monthsAmpicillin plus cefotaxime plus vancomycin*
Age 3 months to 50 yearsCeftriaxone or cefotaxime plus vancomycin*
Older than 50 yearsAmpicillin plus ceftriaxone or cefotaxime plus vancomycin*
Impaired cellular immunityAmpicillin plus ceftazidime plus vancomycin*
Neurosurgery, head trauma, or CSF shuntVancomycin plus ceftazidime
*Vancomycin is added empirically to the initial regimen if the presence of penicillin-resistant S pneumoniae is suspected or if a high incidence of resistance is reported in the community.
Table 8. Recommended Empiric Antibiotics for Patients With Suspected Bacterial Meningitis and Known CSF Gram Stain Results
Gram Stain MorphologyAntibiotic(s)
Gram-positive cocciVancomycin plus ceftriaxone or cefotaxime
Gram-negative cocciPenicillin G*
Gram-positive bacilliAmpicillin plus an aminoglycoside
Gram-negative bacilliBroad-spectrum cephalosporin plus an aminoglycoside
*Use ceftriaxone if penicillin-resistant N meningitidis occurs in the community.



†Ceftriaxone is preferred. Ceftazidime is used when Pseudomonas infection is likely (eg, neurosurgical procedures).



Table 9. Specific Antibiotics and Duration of Therapy for Patients With Acute Bacterial Meningitis
Bacteria Susceptibility Antibiotic(s) Duration



(Days)



S pneumoniaePenicillin MIC < 0.1 mg/LPenicillin G10-14
MIC 0.1-1 mg/LCeftriaxone or cefotaxime
MIC >2 mg/LCeftriaxone or cefotaxime
Ceftriaxone MIC >0.5 mg/LCeftriaxone or cefotaxime plus vancomycin or rifampin
H influenzaeBeta-lactamase-negativeAmpicillin7
Beta-lactamase-positiveCeftriaxone or cefotaxime
N meningitidis...Penicillin G or ampicillin7
L monocytogenes...Ampicillin or penicillin G plus an aminoglycoside14-21
S agalactiae...Penicillin G plus an aminoglycoside, if warranted14-21
Enterobacteriaceae...Ceftriaxone or cefotaxime plus an aminoglycoside21
P aeruginosa...Ceftazidime plus an aminoglycoside21
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.